Bruns Ingmar, Chief Medical Officer of Zentalis Pharmaceuticals ($ZNTL), made two open market sales of company shares in the last year, totaling about $8,000. His most recent sale occurred on February 9, 2026. These sales rank 11,316th among 11,678 insiders in the database, where the average is $8.6 million across about 6.4 transactions per insider. Ingmar had no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 9, 2026 | Zentalis Pharmaceuticals, Inc. | $ZNTL | Bruns Ingmar | Chief Medical Officer | S | Common Stock | 335 | $2.39 | 33,332.0000 | 72,250,779 | 1.00% | 0.00% |
| Feb. 6, 2026 | Zentalis Pharmaceuticals, Inc. | $ZNTL | Bruns Ingmar | Chief Medical Officer | S | Common Stock | 2962 | $2.43 | 33,667.0000 | 72,250,779 | 8.09% | 0.00% |
| Jan. 8, 2026 | Zentalis Pharmaceuticals, Inc. | $ZNTL | Bruns Ingmar | Chief Medical Officer | A | Stock Option (Right to Buy) | 365000 | $0.00 | 365,000.0000 | 72,250,779 | 9999.99% | 0.51% |
| Feb. 6, 2025 | Zentalis Pharmaceuticals, Inc. | $ZNTL | Bruns Ingmar | Chief Medical Officer | P | Common Stock | 20000 | $2.28 | 36,629.0000 | 0 | 120.27% | 0.00% |
| Feb. 3, 2025 | Zentalis Pharmaceuticals, Inc. | $ZNTL | Bruns Ingmar | Chief Medical Officer | A | Common Stock | 16629 | $0.00 | 16,629.0000 | 0 | 9999.99% | 0.00% |
| Feb. 3, 2025 | Zentalis Pharmaceuticals, Inc. | $ZNTL | Bruns Ingmar | Chief Medical Officer | A | Stock Option (Right to Buy) | 16629 | $0.00 | 16,629.0000 | 0 | 9999.99% | 0.00% |
| Dec. 2, 2024 | Zentalis Pharmaceuticals, Inc. | $ZNTL | Bruns Ingmar | Chief Medical Officer | A | Stock Option (Right to Buy) | 712650 | $0.00 | 712,650.0000 | 0 | 9999.99% | 0.00% |